Literature DB >> 15848237

Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.

Hong Yuan1, Sophie Sarre, Guy Ebinger, Yvette Michotte.   

Abstract

We compared the effect of an injection of 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle (MFB) and into the striatum on different parameters for evaluation of motor dysfunction and dopamine denervation in rats, as a function of time. A combination of behavioural, neurochemical and histological techniques was employed. Amphetamine-induced rotation is shown to provide a first rough estimation of motor impairment. Indeed, the number of rotations observed after amphetamine administration can distinguish between a partial and a near complete (>90%) denervation in the substantia nigra. However, lesion sizes of 50-80% resulted in similar rotational behaviour. Similarly, the elevated body swing test (EBST) can determine severe lesions, but is not sensitive enough in the partial model. In both models, determination of the dopamine tissue content with HPLC is a more precise measure of striatal dopamine innervation than striatal TH-immunostaining. The number of cells estimated by TH- and Nissl-staining correlated well in the striatal model, but there was a discrepancy between both measures in the MFB-lesioned animals. Therefore, additional Nissl-staining is necessary for better estimation of the size of the lesion at the level of the substantia nigra or ventral tegmental area in the severely lesioned animals. The MFB lesion model mimics end-stage Parkinson's disease. The striatal injection of 6-OHDA described here cannot be considered a progressive model, since there was no change in the number of TH-immunoreactive cells in the substantia nigra up to 8 weeks post-lesioning. However, the partial denervation renders its quite suitable for mimicking early stage Parkinson's disease, and is thus suitable for testing possible neuroprotective and neurotrophic drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15848237     DOI: 10.1016/j.jneumeth.2004.10.004

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  51 in total

1.  Changes in brain functional activation during resting and locomotor states after unilateral nigrostriatal damage in rats.

Authors:  J Yang; T R Sadler; T K Givrad; J-M I Maarek; D P Holschneider
Journal:  Neuroimage       Date:  2007-03-23       Impact factor: 6.556

2.  Modulation of behavior by expected reward magnitude depends on dopamine in the dorsomedial striatum.

Authors:  Carsten Calaminus; Wolfgang Hauber
Journal:  Neurotox Res       Date:  2009-02-12       Impact factor: 3.911

3.  EPO-dependent activation of PI3K/Akt/FoxO3a signalling mediates neuroprotection in in vitro and in vivo models of Parkinson's disease.

Authors:  Yu Jia; Shi-Jing Mo; Qi-Qi Feng; Ma-Li Zhan; Li-Si OuYang; Jia-Chang Chen; Yu-Xin Ma; Jia-Jia Wu; Wan-Long Lei
Journal:  J Mol Neurosci       Date:  2014-01-04       Impact factor: 3.444

4.  The hydrolysis of striatal adenine- and guanine-based purines in a 6-hydroxydopamine rat model of Parkinson's disease.

Authors:  Jean Pierre Oses; Cristiane Batassini; Daniela Pochmann; Ana Elisa Böhmer; Fernanda Cenci Vuaden; Roberta Bristot Silvestrin; Alcyr Oliveira; Carla Denise Bonan; Maurício Reis Bogo; Diogo Onofre Souza; Luis Valmor Cruz Portela; João José de Freitas Sarkis; Tadeu Mello e Souza
Journal:  Neurochem Res       Date:  2010-11-04       Impact factor: 3.996

5.  Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease.

Authors:  J K Morris; H Zhang; A A Gupte; G L Bomhoff; J A Stanford; P C Geiger
Journal:  Brain Res       Date:  2008-09-11       Impact factor: 3.252

6.  Computational Modeling of Neurotransmitter Release Evoked by Electrical Stimulation: Nonlinear Approaches to Predicting Stimulation-Evoked Dopamine Release.

Authors:  James K Trevathan; Ali Yousefi; Hyung Ook Park; John J Bartoletta; Kip A Ludwig; Kendall H Lee; J Luis Lujan
Journal:  ACS Chem Neurosci       Date:  2017-02-06       Impact factor: 4.418

7.  Nanodelivery of Cerebrolysin and Rearing in Enriched Environment Induce Neuroprotective Effects in a Preclinical Rat Model of Parkinson's Disease.

Authors:  C Requejo; J A Ruiz-Ortega; H Cepeda; A Sharma; H S Sharma; A Ozkizilcik; R Tian; H Moessler; L Ugedo; J V Lafuente
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

8.  Quantifying muscle alterations in a Parkinson's disease animal model using electromyographic biomarkers.

Authors:  Pablo Y Teruya; Fernando D Farfán; Álvaro G Pizá; Jorge H Soletta; Facundo A Lucianna; Ana L Albarracín
Journal:  Med Biol Eng Comput       Date:  2021-07-23       Impact factor: 2.602

9.  The therapeutic effects of tyrosine hydroxylase gene transfected hematopoetic stem cells in a rat model of Parkinson's disease.

Authors:  Shizhong Zhang; Zhihao Zou; Xiaodan Jiang; Ruxiang Xu; Wangming Zhang; Yuan Zhou; Yiquan Ke
Journal:  Cell Mol Neurobiol       Date:  2007-08-23       Impact factor: 5.046

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.